Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 56, Issue 11, 2007, Pages 1458-1463

  Yokoyama, Hiroki ^a   Kannno, Sakiko ^a   Ishimura, Ikue ^a   Node, Koichi ^b  

^a Jiyugaoka Medical Clinic   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; ADIPONECTIN; ALBUMIN; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; MIGLITOL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEINURIA; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TEST MEAL;

1-DEOXYNOJIRIMYCIN; ADIPONECTIN; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IMINO PYRANOSES; MALE; MIDDLE AGED;

EID: 35248894419     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.06.010     Document Type: Article

References (25)

1. Hanefeld M., Fischer S., Julius U., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39 (1996) 1577-1583
2. DECODE Study Group, and European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354 (1999) 617-621
3. Tominaga M., Egichi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 22 (1999) 920-924
4. Ceriello A. The post-prandial state and cardiovascular disease.: relevance to diabetes mellitus. Diabetes Metab Res Rev 16 (2000) 125-132
5. Shadid S., Stehouwer C.D.A., and Jensen M.D. Diet/exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab 91 (2006) 3418-3425
6. Matsuda M., Shimomura I., Sata M., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277 (2002) 37487-37491
7. Valsamakis G., McTernan P.G., Chetty R., et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 53 (2004) 430-434
8. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. A randomized trial. JAMA 289 (2003) 1799-1804
9. Johnston P.S., Lebovitz H.E., Coniff R.F., Simonson D.C., Raskin P., and Munera C.L. Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 83 (1998) 1515-1522
10. Malaisse W.J. Pharmacology of the meglitinide analogues. New treatment options for type 2 diabetes mellitus. Treat Endocrinol 2 (2003) 401-414
11. Scott L.J., and Spencer C.M. Miglitol. A review of its therapeutic potential in type 2 diabetes mellitus. Drugs 59 (2000) 521-549
12. Assaloni R., Da Ros R., Quagliaro L., et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 48 (2005) 1919-1924
13. Dinneen S.F., and Gerstein H.C. The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157 (1997) 1413-1418
14. Gestein H.C., Mann J.F.E., and Yi Q. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
15. van Popele N.M., Grobbee D.E., and Bots M.L. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 32 (2001) 454-460
16. Yokoyama H., Aoki T., and Imahori M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave. Kidney Int 66 (2004) 448-454
17. Cruickshank K., Riste L., and Anderson S.G. Aortic pulse wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 106 (2002) 2085-2090
18. Dungan K.M., Buse J.B., Largay J., et al. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29 (2006) 1214-1219
19. Segal P., Feig P.U., Scherthaner G., et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 20 (1997) 687-691
20. Haffner S.M., Hanefeld M., Fischer S., Focker K., and Leonhardt W. Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care 20 (1997) 1430-1434
21. Rosenstock J., Hassman D.R., Madder R.D., et al. Repaglinide versus nateglinide monotherapy. A randomized, multicenter study. Diabetes Care 27 (2004) 1265-1270
22. Yang W., Lee W., Funahashi T., Tanaka S., et al. Weight reduction increases levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86 (2001) 3815-3819
23. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., and Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116 (2006) 1784-1792
24. Lindsay R.S., Funahashi T., Hanson R.L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
25. Parvanova A.I., Trevisan R., Iliev I.P., et al. Insulin resistance and microalbuminuria. A cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 55 (2006) 1456-1462